Please assess the completion status of the following clinical trial:

Trial Title: Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Parkinson's disease ( Hughes AJ et al. 2001)~* Patients with motor fluctuations~* Chronic Insomnia disorder criteria according to the criteria of DMS- V ( American Psychiatric Association, 2013) and insomnia severity index \> 15~* Able to use independently the device required for treatment by apomorphine~* Collection of written informed consent (legal obligation for any project under the public health law , bioethics laws and / or CNIL) .~* Affiliate to social security or beneficiary of such a regime~Exclusion Criteria:~* Atypical Parkinsonian Syndromes~* Parkinson's disease with dementia (Montreal Cognitive Assessment (MoCA) \<25/30 (NASREDDINE and al., 2012))~  * Parkinson's disease with hallucinations~ * Parkinson's disease with impulse Control disorder (ICD)~ * Parkinson's disease already treated with APOMORPHINE pump or justifying the use of the pump continuously day and night~ * Another obvious severe disease explaining insomnia~ * Exclusion for monitoring difficulties (mutation, insufficient motivation, priority associated pathology in care)~ * Patient unwilling to accept a pump~ * Patient not accepting polysomnography and multiple sleep latency test~ * Patient with health problems or a skin disease precluding continuous subcutaneous infusion~ * Female parturient or nursing~ * Cardiac dysrhythmia precluding treatment with domperidone or apomorphine (increased QTc ≥ 440 ms in men, QTc ≥ 450 ms in women)~ * Treatments forbidden in association with apomorphine such as:~    * antiemetic neuroleptics~   * Tetrabenazine~ * Excessive alcohol consumption~ * Contraindications for apomorphine:~    * Hypersensitivity to apomorphine or one of the excipients~   * Respiratory Depression~   * Hepatic impairment~   * Intellectual Disability~   * Dementia

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Apomorphine (5 mg/ml) (Type: ACTIVE_COMPARATOR): Active phase is apomorphine (from 0.5 mg (0.1 ml) to maximum 5 mg (1 ml)/hour of apomorphine), delivered with a pump (subcutaneous administration), during 22 days.
- Physiologic serum (Type: PLACEBO_COMPARATOR): Physiological serum (from 0.1 ml to maximum 1 ml/ hour), delivered with a pump (subcutaneous administration), during 22 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).